New FDA bonus pilot to address ‘workforce challenges’news2026-03-05T19:40:48+00:00March 5th, 2026|Endpoints News|
Helus Pharma’s stock slides after psychedelic drug data face questions over dosingnews2026-03-05T19:40:48+00:00March 5th, 2026|Endpoints News|
Eli Lilly’s new program aims to boost employer coverage of GLP-1snews2026-03-05T17:02:54+00:00March 5th, 2026|Endpoints News|
BIO chief still backs FDA’s Makary despite ‘head-scratcher’ decisionsnews2026-03-04T15:49:33+00:00March 4th, 2026|Endpoints News|
After years of dispute with FDA, Vanda will get a public hearing for jet lag drugnews2026-03-03T20:21:28+00:00March 3rd, 2026|Endpoints News|
Kyowa Kirin ends OX40 trials after Amgen balked, safety concernnews2026-03-03T20:04:15+00:00March 3rd, 2026|Endpoints News|
EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathwaynews2026-03-03T16:33:03+00:00March 3rd, 2026|Endpoints News|
Corrected: Hims’ pharmacy partner won’t reintroduce GLP-1 pill pulled from marketnews2026-03-03T14:24:24+00:00March 3rd, 2026|Endpoints News|
ICER to CMS: Lower Takeda blockbuster’s price to Stelara’s levelnews2026-03-03T14:03:50+00:00March 3rd, 2026|Endpoints News|
Esperion to buy Corstasis and its nasal spray for edema for $75M upfrontnews2026-03-03T11:56:39+00:00March 3rd, 2026|Endpoints News|
